Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 Dec;85(6):469–473. doi: 10.1136/adc.85.6.469

Vigabatrin associated retinal dysfunction in children with epilepsy

R Koul 1, A Chacko 1, A Ganesh 1, S Bulusu 1, R Al 1
PMCID: PMC1719022  PMID: 11719329

Abstract

BACKGROUND—Recent reports have established that eye changes occur in patients treated with vigabatrin.
AIM—To identify the eye changes associated with vigabatrin, based on a prospective study of children treated for seizures.
METHODS—Twenty nine children on vigabatrin (mainly as add on therapy) were followed up for 6.5 years. Ophthalmic examination was performed before starting treatment and then six monthly in the outpatient clinic.
RESULTS—Twenty one children fulfilled the inclusion criteria. Most had epileptic syndromes with infantile spasms—namely West syndrome, Lennox-Gastaut syndrome, and partial seizures. Vigabatrin dose was 25-114 mg/kg/day (mean 55.8); duration of therapy was 6-85 months (mean 35.7). Four children (19%) developed eye changes (retinal pigmentation, hypopigmented retinal spots, vascular sheathing, and optic atrophy). Visual evoked potentials were abnormal in 16 children. Electroretinography and electro-oculography, which could have picked up eye changes in early stages, were not performed, as this facility was not available.
CONCLUSIONS—Vigabatrin causes eye damage. Most children with epileptic syndromes on vigabatrin cannot complain of their eye problems, hence 3-6 monthly ophthalmic follow up is strongly advised, along with regular electroretinography, electro-oculography, and visual evoked potentials if possible.



Full Text

The Full Text of this article is available as a PDF (128.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aicardi J., Mumford J. P., Dumas C., Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia. 1996 Jul;37(7):638–642. doi: 10.1111/j.1528-1157.1996.tb00627.x. [DOI] [PubMed] [Google Scholar]
  2. Arndt C. F., Derambure P., Defoort-Dhellemmes S., Hache J. C. Outer retinal dysfunction in patients treated with vigabatrin. Neurology. 1999 Apr 12;52(6):1201–1205. doi: 10.1212/wnl.52.6.1201. [DOI] [PubMed] [Google Scholar]
  3. Butler W. H. The neuropathology of vigabatrin. Epilepsia. 1989;30 (Suppl 3):S15–S17. doi: 10.1111/j.1528-1157.1989.tb05827.x. [DOI] [PubMed] [Google Scholar]
  4. Crofts K., Brennan R., Kearney P., O'Connor G. Vigabatrin-induced optic neuropathy. J Neurol. 1997 Oct;244(10):666–667. doi: 10.1007/s004150050165. [DOI] [PubMed] [Google Scholar]
  5. Cubells J. F., Blanchard J. S., Smith D. M., Makman M. H. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther. 1986 Aug;238(2):508–514. [PubMed] [Google Scholar]
  6. Gross-Tsur V., Banin E., Shahar E., Shalev R. S., Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol. 2000 Jul;48(1):60–64. [PubMed] [Google Scholar]
  7. Harding G. F., Wild J. M., Robertson K. A., Rietbrock S., Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology. 2000 Aug 8;55(3):347–352. doi: 10.1212/wnl.55.3.347. [DOI] [PubMed] [Google Scholar]
  8. Johnson M. A., Krauss G. L., Miller N. R., Medura M., Paul S. R. Visual function loss from vigabatrin: effect of stopping the drug. Neurology. 2000 Jul 12;55(1):40–45. doi: 10.1212/wnl.55.1.40. [DOI] [PubMed] [Google Scholar]
  9. Krakow K., Polizzi G., Riordan-Eva P., Holder G., MacLeod W. N., Fish D. R. Recovery of visual field constriction following discontinuation of vigabatrin. Seizure. 2000 Jun;9(4):287–290. doi: 10.1053/seiz.2000.0397. [DOI] [PubMed] [Google Scholar]
  10. Krauss G. L., Johnson M. A., Miller N. R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998 Mar;50(3):614–618. doi: 10.1212/wnl.50.3.614. [DOI] [PubMed] [Google Scholar]
  11. Kutsy R. L., Farrell D. F., Ojemann G. A. Ictal patterns of neocortical seizures monitored with intracranial electrodes: correlation with surgical outcome. Epilepsia. 1999 Mar;40(3):257–266. doi: 10.1111/j.1528-1157.1999.tb00702.x. [DOI] [PubMed] [Google Scholar]
  12. Miller N. R., Johnson M. A., Paul S. R., Girkin C. A., Perry J. D., Endres M., Krauss G. L. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology. 1999 Dec 10;53(9):2082–2087. doi: 10.1212/wnl.53.9.2082. [DOI] [PubMed] [Google Scholar]
  13. Russell-Eggitt I. M., Mackey D. A., Taylor D. S., Timms C., Walker J. W. Vigabatrin-associated visual field defects in children. Eye (Lond) 2000 Jun;14(Pt 3A):334–339. doi: 10.1038/eye.2000.83. [DOI] [PubMed] [Google Scholar]
  14. Vanhatalo S., Päkkönen L., Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology. 1999 May 12;52(8):1713–1714. doi: 10.1212/wnl.52.8.1713. [DOI] [PubMed] [Google Scholar]
  15. Wilson E. A., Brodie M. J. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. BMJ. 1997 Jun 7;314(7095):1693–1693. [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES